Tech Company Financing Transactions
Kinnate Biopharma Funding Round
On 12/20/2019, Kinnate Biopharma raised $74.5 million in Series B investment from Eshelman Ventures, Foresite Capital and Nextech Invest.
Transaction Overview
Company Name
Announced On
12/20/2019
Transaction Type
Venture Equity
Amount
$74,500,000
Round
Series B
Proceeds Purpose
Proceeds from the financing will be used to advance several development candidates from the company's existing programs into the clinic, and to fund new research programs.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
11975 El Camino Real 101
San Diego, CA 92130
USA
San Diego, CA 92130
USA
Phone
Website
Email Address
Not Recorded
Overview
Kinnate Biopharma (Nasdaq: KNTE) is a biopharmaceutical company advancing a pipeline of precision oncology therapeutics to treat patients with genomically defined vulnerabilities.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nima Farzan
Chief Medical Officer
Richard Williams
Chief Operating Officer
Mark Meltz
Chief Scientific Officer
Eric Murphy
Vice President
Robert Kania
Vice President
Eric Martin
Vice President
Sanjeev Thohan
Browse more venture capital transactions:
Prev: 12/20/2019: Forma Therapeutics venture capital transaction
Next: 12/21/2019: Coral venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on all VC transactions involving tech companies. All VC database entries reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs